[Recurrent herpes simplex labialis infections. Possible prevention with a new therapeutic regimen].
Gungner Medical AB, Karolinska Institutet Science Park, Stockholm. johan.harmenberg@gungner.eu
Johan
J
Harmenberg
Spotswood
S
Spruance
D015075:2-Aminopurine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000212:Acyclovir / Q000008:administration & dosage / Q000031:analogs & derivatives; D000287:Administration, Topical; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D000077595:Famciclovir; D006147:Guanine; D006560:Herpes Labialis / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007155:Immunologic Factors / Q000008:administration & dosage; D012008:Recurrence; D016896:Treatment Outcome; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014945:Wound Healing / Q000187:drug effects
D000998:Antiviral Agents; D007155:Immunologic Factors; C053539:penciclovir; D015075:2-Aminopurine; D006147:Guanine; D014633:Valine; D000077483:Valacyclovir; D000077595:Famciclovir; D006854:Hydrocortisone; D000212:Acyclovir